IrsogladinePDE4 inhibitor CAS# 57381-26-7 |
- Gatifloxacin
Catalog No.:BCC1064
CAS No.:112811-59-3
- Dexrazoxane HCl (ICRF-187, ADR-529)
Catalog No.:BCC1087
CAS No.:149003-01-0
- Doxorubicin (Adriamycin) HCl
Catalog No.:BCC1117
CAS No.:25316-40-9
- Etoposide
Catalog No.:BCC1151
CAS No.:33419-42-0
- Genistein
Catalog No.:BCN5499
CAS No.:446-72-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 57381-26-7 | SDF | Download SDF |
| PubChem ID | 5282435 | Appearance | Powder |
| Formula | C9H7Cl2N5 | M.Wt | 256.09 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Dicloguamine | ||
| Solubility | DMSO : ≥ 2.6 mg/mL (10.15 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (Z)-but-2-enedioic acid;6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine | ||
| SMILES | C1=CC(=C(C=C1Cl)C2=NC(=NC(=N2)N)N)Cl.C(=CC(=O)O)C(=O)O | ||
| Standard InChIKey | PJLVTVAIERNDEQ-BTJKTKAUSA-N | ||
| Standard InChI | InChI=1S/C9H7Cl2N5.C4H4O4/c10-4-1-2-6(11)5(3-4)7-14-8(12)16-9(13)15-7;5-3(6)1-2-4(7)8/h1-3H,(H4,12,13,14,15,16);1-2H,(H,5,6)(H,7,8)/b;2-1- | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.
Target: PDE4; mACHR
Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice [1]. Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy [2]. irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions [3]. References: | |||||
Irsogladine Dilution Calculator
Irsogladine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.9049 mL | 19.5244 mL | 39.0488 mL | 78.0975 mL | 97.6219 mL |
| 5 mM | 0.781 mL | 3.9049 mL | 7.8098 mL | 15.6195 mL | 19.5244 mL |
| 10 mM | 0.3905 mL | 1.9524 mL | 3.9049 mL | 7.8098 mL | 9.7622 mL |
| 50 mM | 0.0781 mL | 0.3905 mL | 0.781 mL | 1.562 mL | 1.9524 mL |
| 100 mM | 0.039 mL | 0.1952 mL | 0.3905 mL | 0.781 mL | 0.9762 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P < 0.02, P < 0.001), in tPA-deficient mic
- Isochlorogenic acid C
Catalog No.:BCN2498
CAS No.:57378-72-0
- Bombinakinin-GAP
Catalog No.:BCC5903
CAS No.:573671-91-7
- Dihydroepistephamiersine 6-acetate
Catalog No.:BCN5775
CAS No.:57361-74-7
- Tacalcitol
Catalog No.:BCC1975
CAS No.:57333-96-7
- Congo Red
Catalog No.:BCC8023
CAS No.:573-58-0
- Liriodendrin
Catalog No.:BCN5774
CAS No.:573-44-4
- Boehmenan
Catalog No.:BCN5773
CAS No.:57296-22-7
- Ridaforolimus (Deforolimus, MK-8669)
Catalog No.:BCC4605
CAS No.:572924-54-0
- Boc-D-Phe(4-F)-OH
Catalog No.:BCC3218
CAS No.:57292-45-2
- Boc-D-Phe(4-Cl)-OH
Catalog No.:BCC3176
CAS No.:57292-44-1
- Calmidazolium chloride
Catalog No.:BCC7410
CAS No.:57265-65-3
- Setiptiline
Catalog No.:BCC1945
CAS No.:57262-94-9
- Oroxin A
Catalog No.:BCN1202
CAS No.:57396-78-8
- Benzoin ethyl ether
Catalog No.:BCC8855
CAS No.:574-09-4
- Isoflavone
Catalog No.:BCN8508
CAS No.:574-12-9
- Fraxetin
Catalog No.:BCN5903
CAS No.:574-84-5
- Fexaramine
Catalog No.:BCC7412
CAS No.:574013-66-4
- 8-O-Acetylshanzhiside methyl ester
Catalog No.:BCN5776
CAS No.:57420-46-9
- (2S)-2alpha-(1,3-Benzodioxol-5-yl)-3,5-dihydro-5alpha-methoxy-3beta-methyl-5-allyl-2H-benzofuran-6-one
Catalog No.:BCN6606
CAS No.:57430-03-2
- Methylergometrine maleate
Catalog No.:BCC6691
CAS No.:57432-61-8
- Resiniferatoxin
Catalog No.:BCC6951
CAS No.:57444-62-9
- p-Menth-8-ene-1,2-diol
Catalog No.:BCN5777
CAS No.:57457-97-3
- 2-Epi-3a-epiburchellin
Catalog No.:BCN7013
CAS No.:57457-99-5
- Stigmasta-3,5-diene
Catalog No.:BCC8254
CAS No.:4970-37-0
Irsogladine maleate, a gastric mucosal protectant, suppresses intestinal polyp development in Apc-mutant mice.[Pubmed:26840084]
Oncotarget. 2016 Feb 23;7(8):8640-52.
This study aimed to identify gastric mucosal protectants that suppress intestinal tumorigenesis in a mouse model. We chose six gastric mucosal protectants (ecabet sodium hydrate, Irsogladine maleate, rebamipide, sofalcone, teprenone and troxipide) and examined their effects on the activity of oxidative stress-related transcriptional factors, including AP-1, NF-jB, NRF2, p53 and STAT3, in Caco-2 cells using a luciferase reporter gene assay. Among the six protectants, Irsogladine maleate clearly inhibited NF-jB and AP-1 transcriptional activity. Furthermore, the chemopreventive property of Irsogladine maleate was examined in a Min mouse model of familial adenomatous polyposis. Treatment with Irsogladine maleate at doses of 5 and 50 ppm significantly reduced the number of intestinal polyps to 69% and 66% of the untreated control value, respectively. In these polyps, mRNA levels of the downstream targets of NF-jB, such as IL-1beta and IL-6, were decreased by Irsogladine maleate treatment. Moreover, the levels of oxidative stress-related markers, reactive carbonyl species, in the livers of Min mice were clearly decreased following the administration of Irsogladine maleate. This study demonstrated that Irsogladine maleate suppresses intestinal polyp formation in Min mice partly through the NF-jB signaling pathway, thus reducing oxidative stress.
Development and Characterization of Oral Spray for Stomatitis Containing Irsogladine Maleate.[Pubmed:27628929]
Chem Pharm Bull (Tokyo). 2016 Dec 1;64(12):1659-1665.
The stomatitis caused by anticancer agents and radiation therapy deteriorates patient QOL, potentially causing eating disorders as a result of pain. Although gargling and ointments can be used in the treatment of stomatitis, patients must spit out mouthwash after use, while ointment application requires a finger to be inserted into the oral cavity. In contrast, sprays eliminate these potential compliance problems. Therefore, we developed a stomatitis spray that remains on the oral mucosa. It has been reported that Irsogladine maleate (IM) is effective against stomatitis via oral administration. IM is water insoluble; thus, it was dissolved with various cyclodextrins (CDs). Furthermore, we examined combination with gum ghatti (GG), a mucoadhesive polymer. The interaction between mucin and GG was examined by Quartz Crystal Microbalance with Dissipation monitoring. We found that GG exhibited mucoadhesion. Furthermore, we examined the healing effects of IM on stomatitis in a stomatitis model hamster. We found that stomatitis healed after direct application of IM. However, the model used in this experiment is not based on stomatitis caused by anticancer agents. Further study is therefore necessary.
Effect of long-term proton pump inhibitor therapy and healing effect of irsogladine on nonsteroidal anti-inflammatory drug-induced small-intestinal lesions in healthy volunteers.[Pubmed:26236102]
J Clin Biochem Nutr. 2015 Jul;57(1):60-5.
This study assessed time-course changes of the small intestinal lesions during long-term treatment with diclofenac sodium plus omeprazole and the effects of Irsogladine on such lesions. Thirty two healthy volunteers were treated with diclofenac sodium (75 mg/day) plus omeprazole (10 mg/day) for 6 weeks, with Irsogladine (4 mg/day) added from weeks 6 to 10 (Group A) or with diclofenac sodium plus Irsogladine for 6 weeks (Group B). Five volunteers received diclofenac sodium plus omeprazole for 10 weeks (Group C). Subjects underwent capsule endoscopy at each time. In Group A, the number of lesions remarkably increased at week 2, but the worse was not found at week 6 compared with week 2, whereas no exacerbation of lesions was observed in Group B. Additional treatment with Irsogladine from weeks 6 to 10 in Group A significantly decreased the number of lesions at weeks 10 compared with Group C. In Group C, no significant change in lesions was observed since weeks 2. In conclusions, a PPI did not prevent the occurrence of small intestinal damage. However such lesions were not aggravated since weeks 2. These suggested mucosal adaptation may occur in the small intestine. Irsogladine was effective in both preventing and healing such lesions.
Irsogladine Maleate Prevents Colitis in Interleukin-10 Gene-Deficient Mice by Reducing Interleukin-12 and -23 Production.[Pubmed:26521820]
Biol Pharm Bull. 2015;38(11):1681-8.
Irsogladine maleate (2,4-diamino-6-[2,5-dichlorophenyl]-s-triazine maleate; IM), an anti-peptic ulcer drug, may have a protective effect on the gastrointestinal mucosa. This study investigated the effects of IM on spontaneous colitis in interleukin-10 gene-deficient (IL-10(-/-)) mice. Five-week-old IL-10(-/-) mice were fed a control diet or one containing 100 ppm of IM for 10 weeks. Colonic tissues were evaluated morphologically and histologically. J774A.1 murine monocyte/macrophage cells were incubated with IM after lipopolysaccharide stimulation. mRNA expression was assessed by quantitative polymerase chain reaction (PCR) and protein concentration by enzyme-linked immunosorbent assay (ELISA). Colonic length, weight, and histological scores clearly demonstrated that spontaneous colitis was prevented in IL-10(-/-) mice fed a diet containing IM compared with those fed control diet. Levels of tumor necrosis factor-alpha (TNF-alpha) (-2.5-fold), IL-1beta (-5.4), interferon-gamma (IFN-gamma) (-4.5), IL-17 (-113.0), IL-12p35 (-21.0), IL-12p40 (-3.4), and IL-23p19 (-4.2) mRNA expression were significantly decreased in the colonic tissues of IM-treated animals, suggesting that oral treatment with IM suppressed the T-helper (Th)1/Th17 immune response in the colonic mucosa. An in vitro study using monocyte/macrophage cells to clarify the pharmacological action of IM indicated that IL-12p40 and IL-23p19 mRNA expression levels were dose-dependently decreased by IM treatment. ELISA showed that IL-12p40 and IL-23 protein secretion were significantly decreased by IM in a dose-dependent manner. Oral treatment with IM prevented spontaneous colitis in IL-10(-/-) mice by suppressing the colonic mucosal Th1/Th17 immune response through inhibition of IL-12 and -23 production in monocyte/macrophage cells.
